Creo Medical Group (LON:CREO) Posts Earnings Results

Creo Medical Group (LON:CREO) released its earnings results on Wednesday. The company reported GBX (2) earnings per share for the quarter, Digital Look Earnings reports. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%.

Creo Medical Group Stock Down 13.4%

Shares of LON:CREO traded down GBX 1.59 during trading on Wednesday, hitting GBX 10.28. 7,547,361 shares of the company were exchanged, compared to its average volume of 780,665. The firm’s 50 day moving average price is GBX 12.77 and its 200-day moving average price is GBX 12.87. Creo Medical Group has a 12-month low of GBX 9.52 and a 12-month high of GBX 18.50. The company has a debt-to-equity ratio of 8.20, a current ratio of 3.22 and a quick ratio of 2.19. The stock has a market capitalization of £49.94 million, a P/E ratio of 10.28 and a beta of 1.56.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reissued a “house stock” rating and issued a GBX 40 price objective on shares of Creo Medical Group in a research report on Thursday, July 23rd.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.